Related references
Note: Only part of the references are listed.DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis
Amina Jamal Laham et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Rahul S. Bhansali et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Discovery of 3,6-disubstutited-imidazo[1,2-a]pyridine derivatives as a new class of CLK1 inhibitors
Yun Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes
Kunal Kumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis
Y. Yazici et al.
OSTEOARTHRITIS AND CARTILAGE (2021)
A subcellular map of the human kinome
Haitao Zhang et al.
ELIFE (2021)
A current view on Tau protein phosphorylation in Alzheimer's disease
Susanne Wegmann et al.
CURRENT OPINION IN NEUROBIOLOGY (2021)
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Mattias F. Lindberg et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy
Vishal Deshmukh et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2021)
Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A
Chao Zhao et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2020)
The Dual-Specificity Kinase DYRK1A Modulates the Levels of Cyclin L2 To Control HIV Replication in Macrophages
Javan K. Kisaka et al.
JOURNAL OF VIROLOGY (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation
Simon Dirmeier et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma
Zhile Bai et al.
GENE (2020)
Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential
Paula Martin Moyano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors
Courtney Ackeifi et al.
JCI INSIGHT (2020)
DYRK1A and cognition: A lifelong relationship
Maria L. Arbones et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice
Benoit Souchet et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome
Alba Navarro-Romero et al.
NEUROBIOLOGY OF DISEASE (2019)
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
Benoit Melchior et al.
AGING CELL (2019)
Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice
R. Velazquez et al.
MOLECULAR NEUROBIOLOGY (2019)
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment
V. Deshmukh et al.
OSTEOARTHRITIS AND CARTILAGE (2019)
Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade
Ching-Chi Chiu et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression
Shijiao Tian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment
Ilario De Toma et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
Peng Wang et al.
CELL METABOLISM (2019)
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Jeroni Luna et al.
GUT (2019)
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
Mike A. Nalls et al.
LANCET NEUROLOGY (2019)
Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models
Benoit Souchet et al.
SCIENTIFIC REPORTS (2019)
Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention
Simon Uzor et al.
GENE (2018)
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
Dnyandev B. Jarhad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives
Fernanda Neumann et al.
SCIENTIFIC REPORTS (2018)
Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism
Esti Wahyu Widowati et al.
BIOLOGY OPEN (2018)
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A
Thu Lan Nguyen et al.
DISEASE MODELS & MECHANISMS (2018)
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective
Ankita Pathak et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation
Kunal Kumar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Human cytomegalovirus utilises cellular dual-specificity tyrosine phosphorylation-regulated kinases during placental replication
Stuart T. Hamilton et al.
PLACENTA (2018)
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
Anis Feki et al.
BRAIN SCIENCES (2018)
CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition
Yassan Abdolazimi et al.
ENDOCRINOLOGY (2018)
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Leah J. Wilson et al.
CANCER RESEARCH (2018)
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
Thu Lan Nguyen et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Structural analysis of pathogenic mutations in the DYRK1A gene in patients with developmental disorders
Jochem M. G. Evers et al.
HUMAN MOLECULAR GENETICS (2017)
Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers
Qi-Zheng Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases
Nadege Loaec et al.
MARINE DRUGS (2017)
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome
Harutsugu Tatebe et al.
MOLECULAR NEURODEGENERATION (2017)
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes
Susana Garcia-Cerro et al.
NEUROBIOLOGY OF DISEASE (2017)
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits
Megan Stringer et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2017)
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice
Xiaomin Yin et al.
SCIENTIFIC REPORTS (2017)
Dyrk1 inhibition improves Alzheimer's disease-like pathology
Caterina Branca et al.
AGING CELL (2017)
Comprehensive characterization of the Published Kinase Inhibitor Set
Jonathan M. Elkins et al.
NATURE BIOTECHNOLOGY (2016)
Overexpression of Dyrk1A regulates cardiac troponin T splicing in cells and mice
Shu Lu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Inhibition of DYRK1A Stimulates Human β-Cell Proliferation
Ercument Dirice et al.
DIABETES (2016)
DYRK1A: A Promising Drug Target for Islet Transplant-Based Diabetes Therapies
Bengt-Frederik Belgardt et al.
DIABETES (2016)
DYRK1A inhibition as potential treatment for Alzheimer's disease
Silvia Stotani et al.
FUTURE MEDICINAL CHEMISTRY (2016)
The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome
P. Lee et al.
LEUKEMIA (2016)
Association of DYRK1A polymorphisms with sporadic Parkinson's disease in Chinese Han population
Luan Cen et al.
NEUROSCIENCE LETTERS (2016)
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome
Arnaud Duchon et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2016)
Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice
Gaelle Naert et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE
Nana Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Involvement of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A-Alternative Splicing Factor Calcium/Calmodulin-Dependent Protein Kinase 118 Signaling Pathway in Myocardial Infarction-Induced Heart Failure of Rats
Jing He et al.
JOURNAL OF CARDIAC FAILURE (2015)
The ins and outs of selective kinase inhibitor development
Susanne Mueller et al.
NATURE CHEMICAL BIOLOGY (2015)
A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication
Peng Wang et al.
NATURE MEDICINE (2015)
A historical overview of protein kinases and their targeted small molecule inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2015)
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications
Ramzi Abbassi et al.
PHARMACOLOGY & THERAPEUTICS (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Inhibition of DYRK1A and GSK3B induces human β-cell proliferation
Weijun Shen et al.
NATURE COMMUNICATIONS (2015)
DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner
Thijs Booiman et al.
PLOS ONE (2015)
DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies
Walter Becker et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2014)
Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimer's Disease
Princi Jain et al.
CURRENT DRUG TARGETS (2014)
Phosphorylation of tau protein at sites Ser396-404 is one of the earliest events in Alzheimer's disease and Down syndrome
S. Mondragon-Rodriguez et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
Hydroxybenzothiophene Ketones Are Efficient Pre-mRNA Splicing Modulators Due to Dual Inhibition of Dyrk1A and Clk1/4
Christian Schmitt et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
cdc-Like/Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases Inhibitor Leucettine L41 Induces mTOR-Dependent Autophagy: Implication for Alzheimer's Disease
Xavier Fant et al.
MOLECULAR PHARMACOLOGY (2014)
Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines
Guillaume Burgy et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Distinct Roles of β-Arrestin 1 and β-Arrestin 2 in ORG27569-induced Biased Signaling and Internalization of the Cannabinoid Receptor 1 (CB1)
Kwang H. Ahn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
Natividad Pozo et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome
Xavier Altafaj et al.
NEUROBIOLOGY OF DISEASE (2013)
Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase Activation
Kwang H. Ahn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion
Xiaomin Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome
Sebastien Malinge et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B
Tania Tahtouh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Assessing calcareous sponges and their associated bacteria for the discovery of new bioactive natural products
Melanie Roue et al.
NATURAL PRODUCT REPORTS (2012)
Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A
Shaohong Ding et al.
NEUROBIOLOGY OF AGING (2012)
Pre-mRNA splicing in disease and therapeutics
Ravi K. Singh et al.
TRENDS IN MOLECULAR MEDICINE (2012)
DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles
Sergi Aranda et al.
FASEB JOURNAL (2011)
Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing
Mansour Debdab et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential
Karen J. Gregory et al.
NEUROPHARMACOLOGY (2011)
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A
Wei Qian et al.
NUCLEIC ACIDS RESEARCH (2011)
Genome-Wide Association Study Identifies Single Nucleotide Polymorphism in DYRK1A Associated with Replication of HIV-1 in Monocyte-Derived Macrophages
Sebastiaan M. Bol et al.
PLOS ONE (2011)
MAPT Isoforms: Differential Transcriptional Profiles Related to 3R and 4R Splice Variants
Shufen Chen et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
The SR protein family of splicing factors: master regulators of gene expression
Jennifer C. Long et al.
BIOCHEMICAL JOURNAL (2009)
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome
Jon Ortiz-Abalia et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome
Fei Liu et al.
FASEB JOURNAL (2008)
Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A
Jun-ichiro Yomoda et al.
GENES TO CELLS (2008)
Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome
Jianhua Shi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
DYRK1A-mediated hyperphosphorylation of Tau - A functional link between Down syndrome and Alzheimer disease
Soo-Ryoon Ryoo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Intramolecular C-H amination reactions:: Exploitation of the Rh2(II)-Catalyzed decomposition of azidoacrylates
Benjamin J. Stokes et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease
Ryo Kimura et al.
HUMAN MOLECULAR GENETICS (2007)
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models
I Ferrer et al.
NEUROBIOLOGY OF DISEASE (2005)
Manipulation of alternative splicing by a newly developed inhibitor of Clks
M Muraki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors
M Sechi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bε at Ser539 and the microtubule-associated protein tau at Thr212:: potential role for DYRK as a glycogen synthase kinase 3-priming kinase
YL Woods et al.
BIOCHEMICAL JOURNAL (2001)
A new bioactive triene aldehyde from the marine sponge Leucetta microraphis
K Watanabe et al.
JOURNAL OF NATURAL PRODUCTS (2000)
Share Paper
